Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2025

Genmab — Maj 2025

Planlagt Fastgjort Låst Flyttet Genmab
308 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #276

    Yes I belive Rina-S could be the expectation to a multiblockbuster drug that will change the trend for Genmab.

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bikube
      wrote on sidst redigeret af
      #277

      Jeg får hver dag "BØRS EXTRA" fra Norge. Den udsendes om morgenen før børsåbning til abonnenter, men der er jeg for nærig, så jeg få den over middag. Der står det i, så deres abonn
      enter var informeret før børsen åbnede.

      1 Reply Last reply
      0
      • M Offline
        M Offline
        M_T_A
        wrote on sidst redigeret af
        #278

        Nogen der har nyt om Abbvies søgsmål mod Genmab siden det kom frem?

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #279

          Næ. Det må være lidt op ad bakke at bevise, at man har en dyb hemmelighed, som konkurrenter burde kende alt til....

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #280

            Enig Solsen. Selv om Genmabs situation er noget speciel, så hjælper det med 100% ejerskab og 50% ejerskab, når man regner lidt på mulige fremtider...

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #281

              ASCO25: Genmab's ex-Profound ADC continues to prove mettle in gynecological cancers https://firstwordpharma.com/story/5965833

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #282

                @M_T_A here you can monitor a bit what is happening, but this will probably take a long time, i don't expect to hear any news for the next year...
                https://www.pacermonitor.com/public/case/57357486/AbbVie_Inc_v_Genmab_AS_et_al

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #283

                  Die AbbVie-Aktie könnte bald neuen Rückenwind aus dem Onkologie-Portfolio erhalten. Denn Partner Genmab präsentiert auf der diesjährigen ASCO-Konferenz bahnbrechende Langzeitdaten zu Epcoritamab https://www.aktiencheck.de/news/Artikel-AbbVie_Aktie_Beeindruckende_Ertragserhoehung-18589388

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #284

                    Shicheng Guo
                    @ShihchengGuo
                    New from Stanford & Genmab: UniTox uses GPT-4o to extract drug-induced toxicities from 2,400+ FDA labels into a structured dataset. https://x.com/ShihchengGuo/status/1926138781318385917

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #285

                      a bit more on - Insourcing Cell-line Development Streamlines Antibody Biomanufacturing - https://www.genengnews.com/topics/bioprocessing/insourcing-cell-line-development-streamlines-antibody-biomanufacturing

                      1 Reply Last reply
                      0
                      • M Offline
                        M Offline
                        M_T_A
                        wrote on sidst redigeret af
                        #286

                        @EL thank you so much.

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #287

                          Genmabs fremtidige salg af epcoritamab https://proinvestor.com/boards/126539

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #288

                            GEN1057 moves expected completion dates a year earlier, never really know what it means; either recruitment is going superfast or patients can stay on the drug much shorter as anticipated... anyway, we'll know earlier https://clinicaltrials.gov/study/NCT06573294?tab=history&a=7&b=8#version-content-panel

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #289

                              As the 1057 study is a small phase 1 FIH study the goal is not to look at long term data so in a sense only positive if they can reach conclusions a bit sooner, I guess

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #290

                                It would be nice i their laser sharp focus for once would be positive...

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #291

                                  Do we know if all patients have been enrolled?

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #292

                                    probably
                                    not yet; the status is still 'recruiting' and 2 recruitment centers were just added

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #293

                                      Abbvie arbejder med nye payloads med bedre virkning deres allerede godkendte EMRELIS™ (telisotuzumab vedotin-tllv). Nyt stof ABBV-
                                      400 (Telisotuzumab adizutecan) er værd at følge https://news.abbvie.com/2025-05-27-AbbVie-Features-New-Data-Across-Difficult-to-Treat-Solid-Tumors-and-Blood-Cancers-at-ASCO-2025,-Highlighting-Breadth-and-Depth-of-its-Oncology-Portfolio

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #294

                                        Genmab arbejder med samme indikationer med acasunlimab og nok mere sammenligneligt med deres ADC stof fra Profound - GEN1286

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #295

                                          ABBV-400 stammer fra Immunogen købet til $10bn. ABBV-400 har DAR 6 og artiklen der er linket til nævner SAE som noget vi skal holde øje med https://www.oncologypipeline.com/apexonco/asco-2024-preview-jury-still-out-abbvies-cancer-push Husk at Elahere som også kommer fra nævnte køb også har problematiske SAE (2% fatale). Rina-S er konkurrent til Elahere. Sandelig spændende for Abbvie 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper